According to reports, there are about 129 million adult diabetes patients in my country, ranking first in the world. At present, the overall diabetes control level in my country is not optimistic. The diabetes awareness rate of patients is only 43%, and the treatment rate and control rate are less than 50%. There is an urgent need for hypoglycemia in clinical practice. Insulin therapy with lower risk and smoother blood sugar control can improve this situation. The National Medical Products Administration announced on September 2 the results of the Phase III clinical study based on "Edition AP", formally approving the new formulation of "Insulin Glargine Injection" to be used in adult patients with type 2 diabetes who require insulin treatment . A total of 604 adult type 2 diabetes patients were enrolled in the "Edition AP" Phase III clinical study. The study reached the primary endpoint, confirming the effectiveness and safety of Laiyoushi in the treatment of adult type 2 diabetes.
Based on the overall clinical research results, Professor Ji Linong, director of the Department of Endocrinology, Peking University People’s Hospital and head of Laiyoushi’s registered research in China, said: “Layoushi’s drug action mechanism gives it good sugar control stability and helps patients become more active. And timely dosage adjustment and optimization; coupled with its flexibility in use, it can meet the clinical needs of different patients, improve patient compliance, and achieve long-term effective blood glucose control, helping the majority of patients receiving insulin treatment to further improve the rate of blood glucose control compliance."
The results of another BRIGHT international multicenter randomized controlled study enrolling 929 adults with type 2 diabetes showed that after 24 weeks of treatment, the glycosylated hemoglobin (HbA1c) decreased by 1.64% compared with the baseline; in insulin In the most important initial and dose adjustment stage of treatment, the incidence of hypoglycemia events in the treatment group was significantly reduced by 43% compared with the control group.
Laiyoushi has a specification of 1.5ml: 450 units/pre-filled injection pen. Its unique slow-release mechanism makes the insulin release more slowly and stable after subcutaneous injection, which can provide more stable and effective blood sugar control for diabetic patients and reduce blood sugar fluctuations , Reduce the risk of hypoglycemia, provide a more assured experience of initial volume adjustment and a more flexible injection time window, so as to achieve a more stable and effective blood glucose standard.
Professor Zhu Dalong, director of the Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University School of Medicine, said: “Among the 120 million diabetic patients in my country, most of them are found and diagnosed late. If insulin supplementation or replacement therapy is needed due to disease progression, then basal insulin should It is the first choice. Laiyoushi's advantages such as strong stability and lower risk of hypoglycemia meet the clinical needs that existing insulin cannot meet, and bring new options for the treatment of diabetic patients.
Source: Gade Chemical Network
